1.68
price up icon10.53%   0.16
after-market 시간 외 거래: 1.70 0.02 +1.19%
loading
전일 마감가:
$1.52
열려 있는:
$1.66
하루 거래량:
1.77M
Relative Volume:
5.34
시가총액:
$22.72M
수익:
$1.89M
순이익/손실:
$-17.92M
주가수익비율:
-0.2511
EPS:
-6.69
순현금흐름:
$-15.62M
1주 성능:
+18.31%
1개월 성능:
+40.00%
6개월 성능:
-5.08%
1년 성능:
-48.94%
1일 변동 폭
Value
$1.56
$1.80
1주일 범위
Value
$1.41
$1.80
52주 변동 폭
Value
$1.14
$4.29

Longeveron Inc Stock (LGVN) Company Profile

Name
명칭
Longeveron Inc
Name
전화
305-302-7158
Name
주소
1951 NW 7TH AVENUE, MIAMI
Name
직원
25
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
LGVN's Discussions on Twitter

LGVN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
LGVN
Longeveron Inc
1.68 21.31M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-06 개시 ROTH MKM Buy

Longeveron Inc 주식(LGVN)의 최신 뉴스

pulisher
09:41 AM

Longeveron licenses stem cell patent for heart disease treatment - Investing.com

09:41 AM
pulisher
09:20 AM

Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq

09:20 AM
pulisher
09:17 AM

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times

09:17 AM
pulisher
09:15 AM

Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan

09:15 AM
pulisher
Jul 20, 2025

Longeveron Inc. Stock Analysis and ForecastFree Investment Case Studies - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Longeveron Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is Longeveron Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Longeveron Inc. stock priceMassive wealth growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 16, 2025

What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Longeveron Inc. stock performs during market volatilityFree Stock Market Group - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron® announces U.S. FDA approval of IND application - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World

Jul 02, 2025
pulisher
Jun 26, 2025

Longeveron appoints Than Powell as chief business officer - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewswire

Jun 26, 2025
pulisher
Jun 24, 2025

Longeveron completes enrollment in HLHS pediatric heart trial - Investing.com India

Jun 24, 2025
pulisher
Jun 24, 2025

Longeveron completes enrollment in HLHS pediatric heart trial By Investing.com - Investing.com Nigeria

Jun 24, 2025
pulisher
Jun 18, 2025

Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy - CGTLive®

Jun 18, 2025
pulisher
Jun 13, 2025

Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener

Jun 13, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World

Jun 05, 2025
pulisher
Jun 02, 2025

Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks

Jun 02, 2025
pulisher
May 29, 2025

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance

May 29, 2025
pulisher
May 22, 2025

Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World

May 22, 2025

Longeveron Inc (LGVN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):